Welcome to our dedicated page for Kazia Therapeuti news (Ticker: KZIA), a resource for investors and traders seeking the latest updates and insights on Kazia Therapeuti stock.
Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused drug development and clinical-stage biotechnology company based in Sydney, Australia. News about Kazia typically centers on the progress of its investigational cancer therapies, particularly its lead program paxalisib, as well as pipeline additions such as EVT801 and a first-in-class PD-L1 protein degrader program.
Company announcements frequently highlight clinical and translational data for paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway. Recent news has included results from glioblastoma studies, early efficacy and biomarker findings in advanced triple-negative breast cancer and HER2-positive metastatic breast cancer, and mechanistic data showing reductions in circulating tumor cells and clusters, changes in tumor cell phenotypes, and reinvigoration of immune cell function.
Kazia’s news flow also covers regulatory and development strategy updates, such as its intention to request FDA Type C meetings to discuss overall survival data in newly diagnosed glioblastoma and potential regulatory pathways, as well as participation in initiatives like an Australian Medical Research Future Fund project using AI-enabled platforms to guide therapy sequencing in diffuse midline glioma and diffuse intrinsic pontine glioma.
Investors following KZIA news will also find information on capital markets activities, including private placements of equity securities, at-the-market offerings of American Depositary Shares, and Nasdaq listing compliance developments. Updates on the EVT801 VEGFR3 inhibitor program, the NDL2 PD-L1 degrader collaboration with QIMR Berghofer, and participation in major oncology conferences provide additional context on Kazia’s evolving pipeline and scientific positioning.
This news page aggregates these disclosures so readers can track key milestones in Kazia’s clinical programs, regulatory interactions, collaborations, and financing events over time.
Kazia Therapeutics (NASDAQ: KZIA) on October 7, 2025 announced an exclusive collaboration and in-licensing agreement with QIMR Berghofer for a first-in-class PD-L1 protein degrader program.
The lead optimized compound, NDL2, is described as an advanced PD-L1 protein degrader currently in development and positioned as a novel approach in cancer immunotherapy.
Kazia Therapeutics (NASDAQ: KZIA) reported remarkable results from a single-patient expanded access case using their investigational drug paxalisib. The patient, diagnosed with triple-negative breast cancer (TNBC), showed an 86% reduction in overall tumor burden after just three weeks of combination therapy including paxalisib, immunotherapy, and chemotherapy.
The patient, a 40+ year old female initially diagnosed in April 2023, had previously undergone neoadjuvant therapy and surgery before developing metastatic disease in the bones and lungs. The treatment approach mirrors Kazia's ongoing Phase 1b TNBC study, which evaluates paxalisib in combination with Keytruda® and chemotherapy.
Kazia Therapeutics (NASDAQ: KZIA) announced its participation in an Australian Medical Research Future Fund (MRFF) project focused on developing an AI-driven platform for treating diffuse midline glioma (DMG) and diffuse intrinsic pontine glioma (DIPG). The three-year initiative will establish DMG-ADAPTS, an AI-enabled clinical decision-making platform to optimize therapy sequencing for these aggressive pediatric brain cancers.
The project aims to integrate multiomics profiling with a therapeutic toolkit of twelve brain-penetrant molecules, including Kazia's investigational drug paxalisib, a dual PI3K/mTOR inhibitor. The initiative addresses DMG/DIPG, which accounts for up to 25% of childhood brain cancer deaths with median survival of less than one year. Kazia will provide paxalisib, which has shown encouraging activity in the PNOC 022 pediatric brain cancer trial.
Kazia Therapeutics (NASDAQ: KZIA) has reported breakthrough results from an ex vivo study of paxalisib, their investigational PI3K-mTOR inhibitor, in Stage IV HER2-positive metastatic breast cancer. The study demonstrated that paxalisib monotherapy achieved 100% disruption of circulating tumor cell (CTC) clusters containing three or more cells.
The research, led by Professor Sudha Rao at QIMR Berghofer, revealed significant potential for paxalisib in treating HER2-positive breast cancer, which represents 15-20% of cases. These findings complement Kazia's ongoing Phase 1b trial in triple-negative breast cancer, where initial data from July 2025 showed promising results in reducing CTCs.
Kazia Therapeutics (NASDAQ: KZIA), an oncology-focused drug development company, has secured a $2 million private placement (PIPE) with institutional investors at a 5% premium to the July 31, 2025 closing price. The transaction, expected to close on August 4, 2025, involves ordinary shares and prefunded warrants without common warrant coverage.
The proceeds will support the clinical development of two key programs: paxalisib, a brain-penetrant dual PI3K/mTOR inhibitor in trials for brain cancer and advanced breast cancer, and EVT801, a selective VEGFR3 inhibitor. The company will file a shelf registration statement within 60 days to register the resale of ADSs representing the ordinary shares and those underlying the pre-funded warrants.
Kazia Therapeutics (NASDAQ: KZIA) has reported promising early results from its Phase 1b trial combining Paxalisib with pembrolizumab and standard chemotherapy. The first patient, a 61-year-old woman with metastatic triple-negative breast cancer, showed a greater than 50% reduction in circulating tumor cells (CTCs) after just 21 days of treatment.
The combination therapy demonstrated significant reduction in both single CTCs and CTC clusters, which are known to be 20-100X more efficient at seeding metastases than single CTCs. Notably, the treatment also reduced the mesenchymal phenotype of remaining CTCs, a characteristic associated with aggressive cancer cells.
These early results align with preclinical findings published in Molecular Cancer Therapeutics, suggesting potential effectiveness against metastatic spread. The trial continues to enroll patients to assess safety, tolerability, and pharmacodynamics.
Kazia Therapeutics (NASDAQ: KZIA) has announced the sale of all intellectual property and trademark rights for its oncology drug candidate Cantrixil to Vivesto for USD $1 million. This transaction follows Vivesto's March 2021 licensing of exclusive global development and commercialization rights for the drug.
Vivesto has opted not to pursue Cantrixil's development in ovarian cancer as initially planned, and is instead exploring its potential in hematological cancers through preclinical studies. Cantrixil contains TRXE-002-01, a third-generation benzopyran SMETI inhibitor, encapsulated in α-cyclodextrin.
The sale provides Kazia with non-dilutive funding to support the advancement of their clinical-stage pipeline.